Antibody-drug conjugates on the marchOne of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal Share XAntibody-drug conjugates on the marchhttps://pharmaphorum.com/views-analysis-oncology/antibody-drug-conjugates-on-the-march/
FDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filingThe FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time. The Share XFDA hastily approves Daiichi Sankyo/AZ’s cancer drug, weeks after US filinghttps://pharmaphorum.com/news/fda-hastily-approves-daiichi-sankyo-azs-cancer-drug/
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseaseAstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Share XAZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseasehttps://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Astellas gets EU approval for AML drug XospataThe European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia Share XAstellas gets EU approval for AML drug Xospatahttps://pharmaphorum.com/news/astellas-gets-eu-approval-for-aml-drug-xospata/
AZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewThe FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, Share XAZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewhttps://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/
Astellas maintains lead over Daiichi Sankyo with CHMP okay for XospataAstellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, Share XAstellas maintains lead over Daiichi Sankyo with CHMP okay for Xospatahttps://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
Daiichi waits on FDA as AML drug quizartinib approved in JapanThe Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts Share XDaiichi waits on FDA as AML drug quizartinib approved in Japanhttps://pharmaphorum.com/news/daiichi-waits-on-fda-as-aml-drug-quizartinib-approved-in-japan/
